Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram + oxcarbazepine is a combination of two pharmaceutical drugs used primarily in the management of patients with comorbid epilepsy and depressive disorder. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases serotonin levels in the brain by inhibiting its reuptake, thereby improving mood and anxiety symptoms. Oxcarbazepine is an anticonvulsant that stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, reducing seizure activity. Clinical studies have shown that this combination can be effective for improving both seizure control and depressive symptoms in affected patients, though careful monitoring for drug interactions and side effects is required due to potential pharmacokinetic interactions[2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + oxcarbazepine.